Literature DB >> 22209049

Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.

John D O'Flaherty1, Steven Gray, Derek Richard, Dean Fennell, John J O'Leary, Fiona H Blackhall, Kenneth J O'Byrne.   

Abstract

Circulating tumour cells (CTCs) have attracted much recent interest in cancer research as a potential biomarker and as a means of studying the process of metastasis. It has long been understood that metastasis is a hallmark of malignancy, and conceptual theories on the basis of metastasis from the nineteenth century foretold the existence of a tumour "seed" which is capable of establishing discrete tumours in the "soil" of distant organs. This prescient "seed and soil" hypothesis accurately predicted the existence of CTCs; microscopic tumour fragments in the blood, at least some of which are capable of forming metastases. However, it is only in recent years that reliable, reproducible methods of CTC detection and analysis have been developed. To date, the majority of studies have employed the CellSearch™ system (Veridex LLC), which is an immunomagnetic purification method. Other promising techniques include microfluidic filters, isolation of tumour cells by size using microporous polycarbonate filters and flow cytometry-based approaches. While many challenges still exist, the detection of CTCs in blood is becoming increasingly feasible, giving rise to some tantalizing questions about the use of CTCs as a potential biomarker. CTC enumeration has been used to guide prognosis in patients with metastatic disease, and to act as a surrogate marker for disease response during therapy. Other possible uses for CTC detection include prognostication in early stage patients, identifying patients requiring adjuvant therapy, or in surveillance, for the detection of relapsing disease. Another exciting possible use for CTC detection assays is the molecular and genetic characterization of CTCs to act as a "liquid biopsy" representative of the primary tumour. Indeed it has already been demonstrated that it is possible to detect HER2, KRAS and EGFR mutation status in breast, colon and lung cancer CTCs respectively. In the course of this review, we shall discuss the biology of CTCs and their role in metastagenesis, the most commonly used techniques for their detection and the evidence to date of their clinical utility, with particular reference to lung cancer. Copyright Â
© 2012. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209049     DOI: 10.1016/j.lungcan.2011.10.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  68 in total

Review 1.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR.

Authors:  Ja Hye Myung; Monic Roengvoraphoj; Kevin A Tam; Tian Ma; Vincent A Memoli; Ethan Dmitrovsky; Sarah J Freemantle; Seungpyo Hong
Journal:  Anal Chem       Date:  2015-09-10       Impact factor: 6.986

3.  Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease.

Authors:  Sylvia Plevritis; Alexander R A Anderson; Jill Gallaher; Aravind Babu
Journal:  Cancer Res       Date:  2014-01-09       Impact factor: 12.701

Review 4.  Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

5.  Circulating tumor-derived biomarkers in lung cancer.

Authors:  Aline Taenzer; Catherine Alix-Panabières; Harriet Wikman; Klaus Pantel
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

6.  Circulating tumor cells as emerging tumor biomarkers in lung cancer.

Authors:  Renato Franco; Monica Cantile; Federica Zito Marino; Giuseppe Pirozzi
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

Review 7.  Liquid biopsies in pancreatic cancer.

Authors:  Nabiollah Kamyabi; Vincent Bernard; Anirban Maitra
Journal:  Expert Rev Anticancer Ther       Date:  2019-09-26       Impact factor: 4.512

Review 8.  Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.

Authors:  David Pérez-Callejo; Atocha Romero; Mariano Provencio; María Torrente
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 9.  Circulating tumor cells predict survival benefit from chemotherapy in patients with lung cancer.

Authors:  Zhuo-Xuan Wu; Zhen Liu; Han-Ling Jiang; Hong-Ming Pan; Wei-Dong Han
Journal:  Oncotarget       Date:  2016-10-11

10.  Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.

Authors:  O Juan; J Vidal; R Gisbert; J Muñoz; S Maciá; J Gómez-Codina
Journal:  Clin Transl Oncol       Date:  2013-11-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.